Trial Profile
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Sorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms SorCape
- 04 Apr 2018 Status changed from active, no longer recruiting to completed.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology